About human tumor antigens to be used in immunotherapy

Dudley, 2005, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J Clin Oncol, 23, 2346, 10.1200/JCO.2005.00.240 Van den Eynde B, van der Bruggen P. Peptide database of T-cell defined tumor antigens. Updated in March 2007:URL: http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm. Boon, 1996, Human tumor antigens recognized by T lymphocytes, J Exp Med, 183, 725, 10.1084/jem.183.3.725 Lonchay, 2004, Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen, Proc Natl Acad Sci USA, 101, 14631, 10.1073/pnas.0405743101 Sugaya, 2002, Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy, Chest, 122, 282, 10.1378/chest.122.1.282 Wölfel, 1995, A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma, Science, 269, 1281, 10.1126/science.7652577 Sharkey, 2004, CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation, Cancer Res, 64, 1595, 10.1158/0008-5472.CAN-03-3231 Gjertsen, 1997, Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation, Int J Cancer, 72, 784, 10.1002/(SICI)1097-0215(19970904)72:5<784::AID-IJC14>3.0.CO;2-9 Linard, 2002, A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion, J Immunol, 168, 4802, 10.4049/jimmunol.168.9.4802 Bielas, 2006, Human cancers express a mutator phenotype, Proc Natl Acad Sci USA, 103, 18238, 10.1073/pnas.0607057103 Sjoblom, 2006, The consensus coding sequences of human breast and colorectal cancers, Science, 314, 268, 10.1126/science.1133427 Parmiani, 2007, Unique human tumor antigens: immunobiology and use in clinical trials, J Immunol, 178, 1975, 10.4049/jimmunol.178.4.1975 Chang, 2002, A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer, Clin Cancer Res, 8, 1021 Zhou, 2005, Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine, Cancer Res, 65, 1079, 10.1158/0008-5472.1079.65.3 Belli, 2002, Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings, J Clin Oncol, 20, 4169, 10.1200/JCO.2002.09.134 Haas, 1988, Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis, Am J Reprod Immunol Microbiol, 18, 47, 10.1111/j.1600-0897.1988.tb00234.x Fiszer, 1998, Major histocompatibility complex expression on human, male germ cells: a review, Am J Reprod Immunol, 40, 172, 10.1111/j.1600-0897.1998.tb00409.x De Plaen, 1994, Structure, chromosomal localization and expression of twelve genes of the MAGE family, Immunogenetics, 40, 360, 10.1007/BF01246677 Chomez, 2001, An overview of the MAGE gene family with the identification of all human members of the family, Cancer Res, 61, 5544 Chen, 1997, A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, Proc Natl Acad Sci USA, 94, 1914, 10.1073/pnas.94.5.1914 Lethé, 1998, LAGE-1, a new gene with tumor specificity, Int J Cancer, 76, 903, 10.1002/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1 Gure, 2002, The SSX gene family: characterization of 9 complete genes, Int J Cancer, 101, 448, 10.1002/ijc.10634 De Smet, 1999, DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter, Mol Cell Biol, 19, 7327, 10.1128/MCB.19.11.7327 De Smet, 1996, The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation, Proc Natl Acad Sci USA, 93, 7149, 10.1073/pnas.93.14.7149 Gotter, 2004, Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters, J Exp Med, 199, 155, 10.1084/jem.20031677 Derbinski, 2001, Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self, Nat Immunol, 2, 1032, 10.1038/ni723 Hanagiri, 2006, Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1, Cancer Immunol Immunother, 55, 178, 10.1007/s00262-005-0063-0 Godelaine, 2003, Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide, J Immunol, 171, 4893, 10.4049/jimmunol.171.9.4893 Karanikas, 2003, Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus, J Immunol, 171, 4898, 10.4049/jimmunol.171.9.4898 Anichini, 1993, Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients, J Exp Med, 177, 989, 10.1084/jem.177.4.989 Berger, 2004, Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells, Int J Cancer, 111, 229, 10.1002/ijc.20238 Slingluff, 2003, Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells, J Clin Oncol, 21, 4016, 10.1200/JCO.2003.10.005 Yee, 2000, Melanocyte-destruction after antigen-specific immunotherapy of melanoma: direct evidence of T-cell mediated vitiligo, J Exp Med, 192, 1637, 10.1084/jem.192.11.1637 Powell, 2006, Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion, J Immunol, 177, 6527, 10.4049/jimmunol.177.9.6527 Le Gal, 2001, Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo, J Invest Dermatol, 117, 1464, 10.1046/j.0022-202x.2001.01605.x Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514 Fisk, 1995, Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines, J Exp Med, 181, 2109, 10.1084/jem.181.6.2109 Linehan, 1995, Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer, J Immunol, 155, 4486, 10.4049/jimmunol.155.9.4486 Yoshino, 1994, HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer, Cancer Res, 54, 3387 Ikeda, 1997, Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity, 6, 199, 10.1016/S1074-7613(00)80426-4 Oberthuer, 2004, The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome, Clin Cancer Res, 10, 4307, 10.1158/1078-0432.CCR-03-0813 Van Baren, 1998, PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells, Br J Haematol, 102, 1376, 10.1046/j.1365-2141.1998.00982.x Pellat-Deceunynck, 2000, The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells, Eur J Immunol, 30, 803, 10.1002/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P Epping, 2005, The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling, Cell, 122, 835, 10.1016/j.cell.2005.07.003 Epping, 2006, A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer, Cancer Res, 66, 10639, 10.1158/0008-5472.CAN-06-2522 Greiner, 2006, Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches, Blood, 108, 4109, 10.1182/blood-2006-01-023127 Griffioen, 2006, Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy, Clin Cancer Res, 12, 3130, 10.1158/1078-0432.CCR-05-2578 Schroers, 2002, Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells, Cancer Res, 62, 2600 Vonderheide, 1999, The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytolytic T lymphocytes, Immunity, 10, 673, 10.1016/S1074-7613(00)80066-7 Minev, 2000, Cytotoxic T cell immunity against telomerase reverse transcriptase in humans, Proc Natl Acad Sci USA, 97, 4796, 10.1073/pnas.070560797 Vonderheide, 2004, Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes, Clin Cancer Res, 10, 828, 10.1158/1078-0432.CCR-0620-3 Parkhurst, 2004, Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase, Clin Cancer Res, 10, 4688, 10.1158/1078-0432.CCR-04-0325 Ayyoub, 2001, Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing, Eur J Immunol, 31, 2642, 10.1002/1521-4141(200109)31:9<2642::AID-IMMU2642>3.0.CO;2-6 Inoue, 1997, Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia, Blood, 89, 1405, 10.1182/blood.V89.4.1405 Keilholz, 2005, Wilms’ tumour gene 1 (WT1) in human neoplasia, Leukemia, 19, 1318, 10.1038/sj.leu.2403817 Asemissen, 2006, Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1, Clin Cancer Res, 12, 7476, 10.1158/1078-0432.CCR-06-1337 Oka, 2004, Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression, Proc Natl Acad Sci USA, 101, 13885, 10.1073/pnas.0405884101 Weidanz, 2006, Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing, J Immunol, 177, 5088, 10.4049/jimmunol.177.8.5088 Lethé, 1997, MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific CTL, Melanoma Res, 7, S83 Serrano, 1999, Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries, Int J Cancer, 83, 664, 10.1002/(SICI)1097-0215(19991126)83:5<664::AID-IJC16>3.0.CO;2-V So, 2007, Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules, Cancer Immunol Immunother, 56, 259, 10.1007/s00262-006-0186-y Purbhoo, 2006, Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors, J Immunol, 176, 7308, 10.4049/jimmunol.176.12.7308 Denkberg, 2003, Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen, J Immunol, 171, 2197, 10.4049/jimmunol.171.5.2197 Chames, 2000, Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library, Proc Natl Acad Sci USA, 97, 7969, 10.1073/pnas.97.14.7969 Oosterwijk, 1986, Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney, Int J Cancer, 38, 489, 10.1002/ijc.2910380406 Grabmaier, 2000, Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G 250, Int J Cancer, 85, 865, 10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q McKiernan, 1997, Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma, Cancer Res, 57, 2362 Opavsky, 1996, Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships, Genomics, 33, 480, 10.1006/geno.1996.0223 Vissers, 1999, The renal cell carcinoma-associated antigen G 250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes, Cancer Res, 59, 5554 Vissers, 2002, Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes, Int J Cancer, 100, 441, 10.1002/ijc.10518 Su, 2003, Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells, Cancer Res, 63, 2127 Weijtens, 1996, Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity, J Immunol, 157, 836, 10.4049/jimmunol.157.2.836 Lamers, 2007, Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo, Cancer Immunol Immunother, 56, 1875, 10.1007/s00262-007-0330-3 Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964 Coulie, 2005, Human tumor-specific T lymphocytes: does function matter more than number?, Curr Opin Immunol, 17, 320, 10.1016/j.coi.2005.03.002 Germeau, 2005, High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, J Exp Med, 201, 241, 10.1084/jem.20041379 Lurquin, 2005, Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, J Exp Med, 201, 249, 10.1084/jem.20041378 Khong, 2002, Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy, J Immunol, 168, 951, 10.4049/jimmunol.168.2.951 Butterfield, 2003, Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma, Clin Cancer Res, 9, 998 Disis, 2002, Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines, J Clin Oncol, 20, 2624, 10.1200/JCO.2002.06.171 Lally, 2001, Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading, Int J Cancer, 93, 841, 10.1002/ijc.1420 Vignard, 2005, Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells, J Immunol, 175, 4797, 10.4049/jimmunol.175.7.4797